Sattva Neelapu, MD

Articles

Dr. Neelapu on Managing Toxicities Associated with CAR T-Cell Products in Lymphoma

March 10th 2021

Sattva Neelapu, MD, discusses the management of toxicities associated with CAR T-cell products in patients with lymphoma.

Dr. Neelapu on Emerging CAR T-Cell Therapies in Relapsed/Refractory MCL

February 24th 2021

Sattva Neelapu, MD, discusses emerging CAR T-cell therapies for patients with relapsed/refractory mantle cell lymphoma.

Dr. Neelapu on Potential Advantages of Allogeneic CAR T-Cell Therapy in Lymphoma

July 7th 2020

Sattva Neelapu, MD, discusses the potential advantages of allogeneic CAR T-cell therapy compared with autologous CAR T-cell therapy in lymphoma.

Dr. Neelapu on the Safety Profile of ALLO-501 Plus ALLO-647 in R/R B-Cell Lymphomas

June 29th 2020

Sattva Neelapu, MD, discusses the safety profile of ALLO-501 in combination with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.

Dr. Neelapu on ALLO-501 Plus ALLO-647 in Relapsed/Refractory B-Cell Lymphomas

June 8th 2020

Sattva Neelapu, MD, discusses the mechanism of action of ALLO-501 when paired with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.

Dr. Neelapu on Third-Line CAR T-Cell Therapy in Large B-Cell Lymphoma

July 31st 2019

Sattva Neelapu, MD, discusses the use of CAR T-cell therapy in the third-line setting for patients with large B-cell lymphoma.

Dr. Neelapu Discusses Efficacy of Axi-Cel in Large B-Cell Lymphoma

January 11th 2019

Sattva Neelapu, MD, professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the efficacy of axicabtagene ciloleucel in patients with large B-cell lymphoma.

Combined Radiation Therapy and Checkpoint Inhibition in Lymphoma: A Case Report and Brief Review

March 31st 2018

The emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.

Dr. Neelapu on Updated ZUMA-1 Findings in Non-Hodgkin Lymphoma

December 12th 2017

Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the updated findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) for patients with refractory aggressive non-Hodgkin lymphoma.

Dr. Neelapu on Axi-Cel in the ZUMA-1 Trial for Refractory Aggressive Non-Hodgkin Lymphoma

June 15th 2017

Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; KTE-C19) for patients with refractory aggressive non-Hodgkin lymphoma.